Plasma platelet-activating factor acetylhydrolase (PAF-AH) deficiency as a risk factor for stroke

Brain and Nerve

Volumn 60, Issue 11, 2008, Pages 1319-1324

  Satoh, Kei ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Genetic risk factor; PAF acetylhydrolase; Plasma PAF acetylhydrolase deficiency; Platelet activating factor (PAF); Stroke

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PHENYLALANINE; THROMBOCYTE ACTIVATING FACTOR; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; BRAIN HEMORRHAGE; ENZYME DEFICIENCY; ESSENTIAL HYPERTENSION; GENETIC RISK; HUMAN; INFLAMMATION; JAPANESE; MISSENSE MUTATION; PLATELET ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY; RISK FACTOR; STROKE; THROMBOSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; HUMANS; MUTATION, MISSENSE; PLATELET ACTIVATING FACTOR; RISK FACTORS; STROKE;

EID: 57349178536     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Barbaro JR, Zvaifler J: Antigen induced histamine release from platelets of rabbits producing homologous PCA antibody. Proc Soc Exp Biol Med 122: 1245-1247, 1966
2. Demopoulos CA, Pinckard RN, Hanahan DJ: Platelet-activating factor: evidence for 1-O-alkyl-2-acetyl-sn-gycero-3-phosphorylcholine as the active component (a new class of lipid chemical mediator). J Biol Chem 254: 9355-9358, 1979
3. Blank ML, Lee T, Fitzgerald V, Snyder F: A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypertensive and platelet-activating lipid). J Biol Chem 256: 175-178, 1981
4. Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM: Mammalian platelet-activating factor acetylhydrolases. Biochim Biophys Acta 1301: 161-173, 1996
5. Stafforini DM, McIntyre TM, Carter E, Prescott SM: Plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262: 4215-4222, 1987
6. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, et al: Platelet-activating factor acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97: 2784-2791, 1996
7. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K: A mutation in plasma platelet-activating factor acetylhydrolase (Val279 → Phe) is a genetic risk factor for stroke. Stroke 28: 2417-2420, 1997
8. Imaizumi T, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, et al: Platelet-activating factor: a mediator for clinicians. J Intern Med 238: 5-20, 1995
9. Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, et al: Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274: 28395-28404, 1999
10. Izumi T, Shimizu T: Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1295: 317-333, 1995
11. Japanese source
12. Snyder F, Fitzgerald V, Blank ML: Biosynthesis of platelet-activating factor and enzyme inhibitors. Adv Exp Med Biol 416: 5-10, 1996
13. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet-activating factor acetylhydrolases. J Biol Chem 272: 17895-17898, 1997
14. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, et al: Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease. Prostaglandins 35: 685-698, 1988
15. Satoh K, Yoshida H, Imaizumi T, Takamatsu S, Mizuno S: Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke 23: 1090-1092, 1992
16. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Hiramoto M, et al: Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase in a hepatoma cell line, HepG2. J Clin Invest 87: 476-481, 1991
17. Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, et al: Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem 266: 16667-16673, 1991
18. Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor acetylhydrolase increases during macrophage differentiation: a novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem 264: 8467-8470, 1989
19. Chen DH: Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol 15: 337-341, 2004
20. Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM: An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 262: 4215-4222, 1987
21. Marathe G, Prescott SM, Zimmerman GA, McIntyre TM: Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med 11: 139-142, 2001
22. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40: 643-672, 2003
23. Prescott SM, Zimmerman GA, Stafforini DM: Platelet-activating factor and related lipid mediator. Ann Rev Biochem 69: 419-445, 2000
24. Karasawa K: Clinical aspects of plasma platelet-activating factor. Biochim Biophys Acta 1761: 1359-1372, 2006
25. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, et al: Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82: 1983-1991, 1988
26. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374: 549-553, 1995
27. Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C: Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb Res 101: 231-234, 2001
28. Yamada Y, Yokota M: Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281 → Arg mutation. Biochem Biphys Res Commun 236: 772-775, 1997
29. 2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem Biophys Res Commun 241: 630-635, 1997
30. Yoshida H, Imaizumi T, Fujimoto K, Itaya H, Hiramoto M, et al: A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Thromb Haemost 80: 372-375, 1998
31. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, et al: Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion of neutrophils. J Cell Biol 115: 223-234, 1992
32. Zimmerman GA, McIntyre TM, Prescott SM: Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 98: 1699-1702, 1996
33. Japanese source
34. Japanese source
35. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, et al: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347: 1916-1923, 2002